QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Supplemental Reasoned Position Statement in response to the amended Offer Document published by Thermo Fisher Scientific Inc (NYSE: TMO) on July 17, 2020. The Offer Document relates to the recommended offer by Thermo Fisher to fully acquire all issued ordinary shares in QIAGEN for an increased offer price of €43.00 per QIAGEN share in cash, as announced on July 16, 2020.
QIAGEN has published the Supplemental Reasoned Position Statement of the Managing Board and the Supervisory Board in accordance with Section 27 para. 3 in connection with Section 14 para. 3 of the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetz) and Section 18 para. 2 in connection with Annex G of the Dutch Public Offer Decree (Besluit openbare biedingen Wft).
The Supplemental Reasoned Position Statement, together with the Reasoned Position Statement already published on May 18, 2020, provides in detail the underlying financial and non-financial aspects and the overall circumstances which the Managing Board and Supervisory Board considered when reaffirming their unanimous recommendation of the offer and their unanimous recommendation that all QIAGEN shareholders accept and tender all of their QIAGEN shares in the offer prior to the end of the acceptance period on August 10, 2020. Each of the members of the Supervisory Board and Managing Board has tendered or will tender all of their QIAGEN shares in the offer.
The English and German version of the statement is published on QIAGEN’s website at http://www.qiagen.com/investors. Copies of the German version of the statement can also be obtained free of charge by contacting QIAGEN via e-mail at IR@qiagen.com or by telephone at +49 (0)2103 29 11709.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace